retatrutide clinical trials weight loss retatrutide VisualAbstract: reduces body by 17.5% in patients with obesity Retatrutide Weight Loss Results:Trial Data

Food and Drug Administration or any other regulatory authority for human or veterinary use, diagnosis, or treatment of any condition

Notably, although gallbladder disorders frequently manifest, advanced gastrointestinal complications such as intestinal obstruction and periprocedural aspiration, and emergent concerns regarding suicidality and ocular problems require further longitudinal studies to refine the usage guidelines for GLP-1 RAs in susceptible populations

Maybe you want the additional weight loss tirzepatide offers

A small addition can significantly change the outcome

This includes eligibility screening, dose titration, a critical phase in tirzepatide therapy where doses advance from the 2.5 mg starting dose through escalating levels (5 mg, 7.5 mg, 10 mg, and 12.5 mg or 15 mg), and ongoing monitoring of metabolic and clinical outcomes

GLP-1 receptor agonists improve insulin sensitivity and glucose control